首页 › 卵巢癌 › 得克萨斯州 › Fort Worth
Fort Worth TX 卵巢癌临床试验
17项针对 卵巢癌的研究正在 Fort Worth及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
招募中2/3 期
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- START Center for Cancer Research - Texas, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
招募中2 期
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
招募中3 期
- Texas Oncology - DFW ( Site 8005), Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
招募中2 期
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中3 期
- Jps Health Network, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Start Dfw, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Start - Dfw, Fort Worth
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
招募中3 期
- Texas Oncology - DFW ( Site 8001), Fort Worth
Study of NTB-928 in R/R OC
招募中1 期
- Start Ccbd, Llc, Fort Worth
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
招募中1 期
- Xencor Investigative Site, Fort Worth
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Texas Oncology, Fort Worth
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
招募中2/3 期
- Texas Oncology Paris, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
招募中1 期
- START Dallas, Fort Worth
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
招募中2 期
- SCRI - Texas Oncology, Fort Worth
其他城市的 卵巢癌试验
- Houston, TX89 项研究
- New York City, NY69 项研究
- Boston, MA61 项研究
- Los Angeles, CA50 项研究
- Nashville, TN49 项研究
- Arlington, VA46 项研究
- Philadelphia, PA44 项研究
- Columbus, OH39 项研究
- St. Louis, MO38 项研究
- Chicago, IL36 项研究
- San Antonio, TX31 项研究
- Cleveland, OH30 项研究
Fort Worth的其他研究
- 非小细胞肺癌18 项研究
- 子宫内膜癌12 项研究
- 乳腺癌12 项研究
- 癌症（所有类型）9 项研究
- 前列腺癌9 项研究
- 三阴性乳腺癌7 项研究
- 黄斑变性7 项研究
- 溃疡性结肠炎7 项研究
- 肾癌（肾细胞癌）7 项研究
- 心力衰竭7 项研究
- 转移性癌症7 项研究
- 结直肠癌7 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。